Key Takeaways
- HEOR evidence remains vital for drug reimbursement and market access despite corporate restructuring.
- Integration of AI and digital tools is enhancing real-world data analysis and evidence generation.
- Strategic storytelling and demonstrating HEOR’s impact can strengthen its position within organizations.
- Collaboration with industry partners is essential to address evolving healthcare challenges and regulatory requirements.
In the latest issue of Value and Outcomes Spotlight, ISPOR’s CEO Rob Abbott addresses the evolving landscape of Health Economics and Outcomes Research (HEOR) amidst significant restructuring within global biopharmaceutical firms. Abbott highlights the critical role HEOR professionals play in generating robust evidence essential for securing drug coverage and reimbursement in an increasingly competitive and regulated market.
Over the past year, numerous HEOR groups within leading biopharma companies have experienced layoffs and strategic realignments, often being merged into Market Access or Medical Affairs departments. While corporate reorganizations are a common occurrence, the targeted dismantling of HEOR units coincides with heightened regulatory demands for comprehensive evidence encompassing clinical, economic, and patient-centered outcomes. This shift underscores the necessity for HEOR scientists to adapt and continue contributing valuable insights despite organizational changes.
HEOR’s Role in Advancing Healthcare Innovation
Abbott emphasizes that HEOR is pivotal in demonstrating both the clinical superiority and cost-effectiveness of new therapies. He cites successful case studies such as Eliquis and antiretroviral therapies for HIV, where strategic evidence generation and access strategies were fundamental in achieving widespread adoption and affordability.
These examples illustrate how HEOR contributes to expanding drug labels and ensuring that innovative treatments reach larger patient populations efficiently.
Looking Ahead: Strengthening HEOR’s Influence
Abbott outlines ISPOR’s ambitious strategy to harness HEOR in making healthcare more accessible, effective, and affordable globally. By improving evidence-generation methodologies and leveraging advanced technologies like generative AI, ISPOR aims to empower HEOR professionals to produce credible and actionable insights. These efforts are designed to reduce uncertainty for healthcare decision-makers and align HEOR activities with broader business objectives, thereby enhancing its strategic value within the healthcare ecosystem.
To achieve these goals, HEOR must transition from being perceived solely as an academic pursuit to a multidisciplinary field that drives innovation and informs critical healthcare decisions. By showcasing the tangible impacts of HEOR on drug development and patient outcomes, professionals can advocate for its indispensable role in the industry. The integration of AI capabilities promises to further elevate HEOR’s analytical power, enabling more sophisticated real-world evidence and fostering evidence-based healthcare advancements.
Ultimately, HEOR scientists possess the expertise necessary to navigate the complexities of modern healthcare, ensuring that new treatments deliver genuine value. As the healthcare landscape continues to evolve, the contributions of HEOR will remain essential in bridging the gap between innovation and patient access, securing a future where effective and affordable healthcare is within reach for all.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
